Device/Diagnostics Quarterly Deal Statistics, Q4 2014
A look at financing, M&A, and alliance activity October–December 2014
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
You may also be interested in...
The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.
In many ways, the year in diagnostics can be characterized as “more of the same.” The biggest newsmaker was FDA’s finally taking steps toward establishing an oversight framework for the regulation of laboratory-developed tests.
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.